18224865. GENERATION OF ANTI-TUMOR T CELLS simplified abstract (DANA-FARBER CANCER INSTITUTE, INC.)
Contents
- 1 GENERATION OF ANTI-TUMOR T CELLS
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 GENERATION OF ANTI-TUMOR T CELLS - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
GENERATION OF ANTI-TUMOR T CELLS
Organization Name
DANA-FARBER CANCER INSTITUTE, INC.
Inventor(s)
Catherine J. Wu of Brookline MA (US)
Giacomo Oliveira of Boston MA (US)
GENERATION OF ANTI-TUMOR T CELLS - A simplified explanation of the abstract
This abstract first appeared for US patent application 18224865 titled 'GENERATION OF ANTI-TUMOR T CELLS
Simplified Explanation
The patent application focuses on methods for identifying expanded, exhausted, and tumor-specific T-cell clonotypes for adoptive cell transfer, as well as methods of cancer treatment and modified T cells with anti-tumor T cell receptors (TCRs).
- Methods for identifying expanded, exhausted, and tumor-specific T-cell clonotypes for adoptive cell transfer.
- Methods of cancer treatment using modified T cells with anti-tumor TCRs.
Potential Applications
The technology can be applied in the field of cancer immunotherapy for developing personalized treatments based on tumor-specific T-cell clonotypes.
Problems Solved
This technology addresses the challenge of identifying and targeting specific T-cell clonotypes that are effective against tumors, potentially improving the success rate of adoptive cell transfer therapies.
Benefits
- Enhanced precision in targeting tumor-specific T-cell clonotypes - Improved efficacy of cancer treatments - Personalized approach to cancer immunotherapy
Potential Commercial Applications
The technology can be utilized by biopharmaceutical companies for developing novel cancer immunotherapies with improved efficacy and personalized treatment options.
Possible Prior Art
Prior art may include existing methods for identifying T-cell clonotypes in cancer immunotherapy research, as well as prior patents related to adoptive cell transfer technologies.
Unanswered Questions
How does this technology compare to existing methods for identifying T-cell clonotypes in cancer immunotherapy?
The article does not provide a direct comparison to existing methods or technologies in the field.
What are the potential limitations or challenges associated with implementing this technology in clinical settings?
The article does not address any potential limitations or challenges that may arise when implementing this technology in clinical practice.
Original Abstract Submitted
Disclosed are methods for identifying expanded, exhausted, and tumor-specific T-cell clonotypes for adoptive cell transfer, and methods of cancer treatment and modified T cells with anti-tumor T cell receptors (TCRs).
